WEBINAR ON DEMAND
Duration: 1 hour

Most (90%) of drug candidates fail to reach the commercial market—and among those failures, most (90%, again) are linked to suboptimal target selection. With a product’s odds of success so staked on good target characterization, scientists are always looking for the best way to create a supportive foundation during drug discovery.  Single-cell RNA sequencing (scRNA-seq) is a proven practice that’s well familiar to academic researchers to do exactly that, but its uptake among biopharma organizations is not as robust. Could the current needs of drug discovery researchers change that? 

Virginia Savova, PhD, Strategic and Scientific Advisor at Scailyte, says it might. She was a leader of a Global Single-cell Biology group, focusing on target and biomarker discovery across immune indications. Furthermore, she combines deep knowledge in computational biology, immunology, and cancer research with experience in leveraging AI for drug discovery and development. In this webinar from BioPharma Dive, Savova explores the utility and value of single cell analysis in the drug development continuum. You’ll learn:

• The value of using target identification within the drug discovery process
• How scRNA-seq can improve biomarker discovery and the drug development process
• The current state of scRNA-seq uptake in the pharma industry, including barriers preventing more widespread utilization
• Anticipated use cases for scRNA-seq in the near future

SPEAKERS

Virginia Savova, PhD
Strategic and Scientific Advisor
Scailyte